Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) and CDT Equity (NASDAQ:CDT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.
Analyst Ratings
This is a summary of current recommendations for Reviva Pharmaceuticals and CDT Equity, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Reviva Pharmaceuticals | 1 | 2 | 5 | 0 | 2.50 |
| CDT Equity | 1 | 0 | 0 | 0 | 1.00 |
Reviva Pharmaceuticals presently has a consensus price target of $66.67, indicating a potential upside of 11,011.11%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Reviva Pharmaceuticals is more favorable than CDT Equity.
Risk and Volatility
Insider and Institutional Ownership
63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Reviva Pharmaceuticals and CDT Equity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Reviva Pharmaceuticals | N/A | -391.58% | -119.08% |
| CDT Equity | N/A | -4,263.33% | -529.91% |
Earnings and Valuation
This table compares Reviva Pharmaceuticals and CDT Equity”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Reviva Pharmaceuticals | N/A | N/A | -$19.86 million | ($4.06) | -0.15 |
| CDT Equity | N/A | N/A | -$39.22 million | ($66,338.55) | 0.00 |
Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.
Summary
Reviva Pharmaceuticals beats CDT Equity on 8 of the 11 factors compared between the two stocks.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
About CDT Equity
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
